Modeling	B:C0870071
the	O
ferrochelatase	O
c.315-48C	I:C1414580
modifier	O
mutation	O
for	O
erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
in	O
mice	O
.	O

Modeling	O
the	O
ferrochelatase	B:C1414580
c.315-48C	I:C1414580
modifier	O
mutation	O
for	O
erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
in	O
mice	O
.	O

Modeling	O
the	O
ferrochelatase	O
c.315-48C	I:C1414580
modifier	O
mutation	B:C0026882
for	O
erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
in	O
mice	O
.	O

Modeling	O
the	O
ferrochelatase	O
c.315-48C	I:C1414580
modifier	O
mutation	O
for	O
erythropoietic	B:C0162568
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
in	O
mice	O
.	O

Modeling	O
the	O
ferrochelatase	O
c.315-48C	I:C1414580
modifier	O
mutation	O
for	O
erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	B:C0162568
protoporphyria	I:C0162568
)	O
in	O
mice	O
.	O

Modeling	O
the	O
ferrochelatase	O
c.315-48C	I:C1414580
modifier	O
mutation	O
for	O
erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
in	O
mice	B:C0026809
.	O

Erythropoietic	B:C0162568
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	B:C0162568
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	B:C0015880
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	B:C0015880
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	B:C0302583
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	B:C0072497
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	B:C0072497
IX	I:C0072497
)	O
to	O
form	O
heme	O
.	O

Erythropoietic	O
protoporphyria	I:C0162568
(	O
erythropoietic	O
protoporphyria	I:C0162568
)	O
is	O
caused	O
by	O
deficiency	O
of	O
ferrochelatase	O
(	O
ferrochelatase	O
)	O
,	O
which	O
incorporates	O
iron	O
into	O
protoporphyrin	O
IX	I:C0072497
(	O
protoporphyrin	O
IX	I:C0072497
)	O
to	O
form	O
heme	B:C0018966
.	O

Excitation	O
of	O
accumulated	O
protoporphyrin	B:C0072497

IX	I:C0072497
by	O
light	O
generates	O
oxygen	O
radicals	O
that	O
evoke	O
excessive	O
pain	B:C0030193
and	O
,	O
after	O
longer	O
light	O
exposure	O
,	O
cause	O
ulcerations	O
in	O
exposed	O
skin	O
areas	O
of	O
individuals	O
with	O
erythropoietic	O
protoporphyria	I:C0162568
.	O

IX	I:C0072497
by	O
light	O
generates	O
oxygen	O
radicals	O
that	O
evoke	O
excessive	O
pain	O
and	O
,	O
after	O
longer	O
light	O
exposure	O
,	O
cause	O
ulcerations	B:C0041582
in	O
exposed	O
skin	O
areas	O
of	O
individuals	O
with	O
erythropoietic	O
protoporphyria	I:C0162568
.	O

IX	I:C0072497
by	O
light	O
generates	O
oxygen	O
radicals	O
that	O
evoke	O
excessive	O
pain	O
and	O
,	O
after	O
longer	O
light	O
exposure	O
,	O
cause	O
ulcerations	O
in	O
exposed	O
skin	B:C1123023
areas	O
of	O
individuals	O
with	O
erythropoietic	O
protoporphyria	I:C0162568
.	O

IX	I:C0072497
by	O
light	O
generates	O
oxygen	O
radicals	O
that	O
evoke	O
excessive	O
pain	O
and	O
,	O
after	O
longer	O
light	O
exposure	O
,	O
cause	O
ulcerations	O
in	O
exposed	O
skin	O
areas	O
of	O
individuals	B:C0237401
with	O
erythropoietic	O
protoporphyria	I:C0162568
.	O

IX	I:C0072497
by	O
light	O
generates	O
oxygen	O
radicals	O
that	O
evoke	O
excessive	O
pain	O
and	O
,	O
after	O
longer	O
light	O
exposure	O
,	O
cause	O
ulcerations	O
in	O
exposed	O
skin	O
areas	O
of	O
individuals	O
with	O
erythropoietic	B:C0162568
protoporphyria	I:C0162568
.	O

Moreover	O
,	O
∼5	O
%	O
of	O
the	O
patients	O
develop	O
a	O
liver	B:C0086565
dysfunction	I:C0086565
as	O
a	O
result	O
of	O
protoporphyrin	O
IX	I:C0072497
accumulation	O
.	O

Moreover	O
,	O
∼5	O
%	O
of	O
the	O
patients	O
develop	O
a	O
liver	O
dysfunction	I:C0086565
as	O
a	O
result	O
of	O
protoporphyrin	B:C0072497
IX	I:C0072497
accumulation	O
.	O

Moreover	O
,	O
∼5	O
%	O
of	O
the	O
patients	O
develop	O
a	O
liver	O
dysfunction	I:C0086565
as	O
a	O
result	O
of	O
protoporphyrin	O
IX	I:C0072497
accumulation	B:C4055506
.	O

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	B:C1414580
mutation	O
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	O
)	O
,	O
which	O
reduces	O
ferrochelatase	O
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	O
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	O
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	O
4	I:C0015295
.	I:C0015295

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	O
mutation	B:C1881249
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	O
)	O
,	O
which	O
reduces	O
ferrochelatase	O
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	O
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	O
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	O
4	I:C0015295
.	I:C0015295

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	O
mutation	O
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	B:C1414580
)	O
,	O
which	O
reduces	O
ferrochelatase	O
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	O
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	O
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	O
4	I:C0015295
.	I:C0015295

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	O
mutation	O
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	O
)	O
,	O
which	O
reduces	O
ferrochelatase	B:C0015880
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	O
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	O
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	O
4	I:C0015295
.	I:C0015295

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	O
mutation	O
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	O
)	O
,	O
which	O
reduces	O
ferrochelatase	O
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	B:C1158733
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	O
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	O
4	I:C0015295
.	I:C0015295

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	O
mutation	O
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	O
)	O
,	O
which	O
reduces	O
ferrochelatase	O
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	O
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	B:C1710582
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	O
4	I:C0015295
.	I:C0015295

Most	O
patients	O
(	O
∼97	O
%	O
)	O
have	O
a	O
severe	O
ferrochelatase	O
mutation	O
(	I:C1881249
Mut	I:C1881249
)	I:C1881249
in	I:C1881249
trans	I:C1881249
to	I:C1881249
an	I:C1881249
intronic	I:C1881249
polymorphism	O
(	O
c.315-48C	O
)	O
,	O
which	O
reduces	O
ferrochelatase	O
synthesis	O
by	O
stimulating	O
the	O
use	O
of	O
an	O
aberrant	O
3	O
'	I:C1158733
splice	I:C1158733
site	I:C1158733
63	O
nt	I:C1710582
upstream	I:C1710582
of	I:C1710582
the	I:C1710582
normal	I:C1710582
site	I:C1710582
for	O
exon	B:C0015295
4	I:C0015295
.	I:C0015295

In	O
contrast	O
,	O
with	O
the	O
predominant	O
c.315-48T	B:C1414580
allele	O
,	O
the	O
correct	O
splice	O
site	I:C1711332
is	O
mostly	O
used	O
,	O
and	O
individuals	O
with	O
a	O
T	O
/	I:C0026882
Mut	I:C0026882
genotype	O
do	O
not	O
develop	O
erythropoietic	O
protoporphyria	I:C0162568
symptoms	O
.	O

In	O
contrast	O
,	O
with	O
the	O
predominant	O
c.315-48T	O
allele	B:C0002085
,	O
the	O
correct	O
splice	O
site	I:C1711332
is	O
mostly	O
used	O
,	O
and	O
individuals	O
with	O
a	O
T	O
/	I:C0026882
Mut	I:C0026882
genotype	O
do	O
not	O
develop	O
erythropoietic	O
protoporphyria	I:C0162568
symptoms	O
.	O

In	O
contrast	O
,	O
with	O
the	O
predominant	O
c.315-48T	O
allele	O
,	O
the	O
correct	O
splice	B:C1711332
site	I:C1711332
is	O
mostly	O
used	O
,	O
and	O
individuals	O
with	O
a	O
T	O
/	I:C0026882
Mut	I:C0026882
genotype	O
do	O
not	O
develop	O
erythropoietic	O
protoporphyria	I:C0162568
symptoms	O
.	O

In	O
contrast	O
,	O
with	O
the	O
predominant	O
c.315-48T	O
allele	O
,	O
the	O
correct	O
splice	O
site	I:C1711332
is	O
mostly	O
used	O
,	O
and	O
individuals	O
with	O
a	O
T	B:C0026882
/	I:C0026882
Mut	I:C0026882
genotype	O
do	O
not	O
develop	O
erythropoietic	O
protoporphyria	I:C0162568
symptoms	O
.	O

In	O
contrast	O
,	O
with	O
the	O
predominant	O
c.315-48T	O
allele	O
,	O
the	O
correct	O
splice	O
site	I:C1711332
is	O
mostly	O
used	O
,	O
and	O
individuals	O
with	O
a	O
T	O
/	I:C0026882
Mut	I:C0026882
genotype	O
do	O
not	O
develop	O
erythropoietic	B:C0162568
protoporphyria	I:C0162568
symptoms	O
.	O

In	O
contrast	O
,	O
with	O
the	O
predominant	O
c.315-48T	O
allele	O
,	O
the	O
correct	O
splice	O
site	I:C1711332
is	O
mostly	O
used	O
,	O
and	O
individuals	O
with	O
a	O
T	O
/	I:C0026882
Mut	I:C0026882
genotype	O
do	O
not	O
develop	O
erythropoietic	O
protoporphyria	I:C0162568
symptoms	B:C1457887
.	O

Thus	O
,	O
the	O
C	B:C0002085
allele	I:C0002085
is	O
a	O
potential	O
target	O
for	O
therapeutic	O
approaches	I:C0087111
that	O
modify	O
this	O
splicing	O
decision	O
.	O

Thus	O
,	O
the	O
C	O
allele	I:C0002085
is	O
a	O
potential	O
target	O
for	O
therapeutic	B:C0087111
approaches	I:C0087111
that	O
modify	O
this	O
splicing	O
decision	O
.	O

Thus	O
,	O
the	O
C	O
allele	I:C0002085
is	O
a	O
potential	O
target	O
for	O
therapeutic	O
approaches	I:C0087111
that	O
modify	O
this	O
splicing	B:C0017387
decision	O
.	O

To	O
provide	O
a	O
model	B:C3161035
for	O
pre-clinical	O
studies	I:C0013206
of	O
such	O
approaches	O
,	O
we	O
engineered	O
a	O
mouse	O
containing	O
a	O
partly	O
humanized	O
Fech	O
gene	I:C1414580
with	O
the	O
c.315-48C	O
polymorphism	O
.	O

To	O
provide	O
a	O
model	O
for	O
pre-clinical	B:C0013206
studies	I:C0013206
of	O
such	O
approaches	O
,	O
we	O
engineered	O
a	O
mouse	O
containing	O
a	O
partly	O
humanized	O
Fech	O
gene	I:C1414580
with	O
the	O
c.315-48C	O
polymorphism	O
.	O

To	O
provide	O
a	O
model	O
for	O
pre-clinical	O
studies	I:C0013206
of	O
such	O
approaches	O
,	O
we	O
engineered	O
a	O
mouse	B:C0026809
containing	O
a	O
partly	O
humanized	O
Fech	O
gene	I:C1414580
with	O
the	O
c.315-48C	O
polymorphism	O
.	O

To	O
provide	O
a	O
model	O
for	O
pre-clinical	O
studies	I:C0013206
of	O
such	O
approaches	O
,	O
we	O
engineered	O
a	O
mouse	O
containing	O
a	O
partly	O
humanized	O
Fech	B:C1414580
gene	I:C1414580
with	O
the	O
c.315-48C	O
polymorphism	O
.	O

To	O
provide	O
a	O
model	O
for	O
pre-clinical	O
studies	I:C0013206
of	O
such	O
approaches	O
,	O
we	O
engineered	O
a	O
mouse	O
containing	O
a	O
partly	O
humanized	O
Fech	O
gene	I:C1414580
with	O
the	O
c.315-48C	B:C1414580
polymorphism	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	B:C0026809
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	B:C1414580
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	B:C0026882
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	B:C1414580
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	B:C0162568
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	B:C0072497
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	B:C0005767
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	B:C1112137
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	B:C0002871
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	B:C0030193
reactions	O
and	O
skin	O
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

F1	O
hybrids	O
obtained	O
by	O
crossing	O
these	O
mice	O
with	O
another	O
inbred	O
line	O
carrying	O
a	O
severe	O
Fech	O
mutation	O
(	O
named	O
m1	O
Pas	I:C1414580
)	O
show	O
a	O
very	O
strong	O
erythropoietic	O
protoporphyria	I:C0162568
phenotype	O
that	O
includes	O
elevated	O
protoporphyrin	O
IX	I:C0072497
in	O
the	O
blood	O
,	O
enlargement	O
of	I:C1112137
liver	I:C1112137
and	I:C1112137
spleen	I:C1112137
,	O
anemia	O
,	O
as	O
well	O
as	O
strong	O
pain	O
reactions	O
and	O
skin	B:C0037284
lesions	I:C0037284
after	O
a	O
short	O
period	O
of	O
light	O
exposure	O
.	O

In	O
addition	O
to	O
the	O
expected	O
use	O
of	O
the	O
aberrant	O
splice	B:C1711332
site	I:C1711332
,	O
the	O
mice	O
also	O
show	O
a	O
strong	O
skipping	O
of	O
the	O
partly	O
humanized	O
exon	O
3	I:C0015295
.	O

In	O
addition	O
to	O
the	O
expected	O
use	O
of	O
the	O
aberrant	O
splice	O
site	I:C1711332
,	O
the	O
mice	B:C0026809
also	O
show	O
a	O
strong	O
skipping	O
of	O
the	O
partly	O
humanized	O
exon	O
3	I:C0015295
.	O

In	O
addition	O
to	O
the	O
expected	O
use	O
of	O
the	O
aberrant	O
splice	O
site	I:C1711332
,	O
the	O
mice	O
also	O
show	O
a	O
strong	O
skipping	O
of	O
the	O
partly	O
humanized	O
exon	B:C0015295
3	I:C0015295
.	O

This	O
will	O
limit	O
the	O
use	O
of	O
this	O
model	B:C3161035
for	O
certain	O
applications	O
and	O
illustrates	O
that	O
engineering	O
of	O
a	O
hybrid	O
gene	O
may	O
have	O
unforeseeable	O
consequences	O
on	O
its	O
splicing	O
.	O

This	O
will	O
limit	O
the	O
use	O
of	O
this	O
model	O
for	O
certain	O
applications	O
and	O
illustrates	O
that	O
engineering	O
of	O
a	O
hybrid	O
gene	O
may	O
have	O
unforeseeable	O
consequences	O
on	O
its	O
splicing	B:C0017387
.	O

